Breaking Down Hangzhou Changchuan Technology Co.,Ltd Financial Health: Key Insights for Investors

Breaking Down Hangzhou Changchuan Technology Co.,Ltd Financial Health: Key Insights for Investors

CN | Technology | Semiconductors | SHZ

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) Bundle

Get Full Bundle:
$25 $15
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7
$9 $7

TOTAL:

Curious whether Hangzhou Changchuan Technology Co., Ltd. (300604.SZ) is riding a true growth wave or trading on high expectations? In the first half of 2025 the company reported revenue of ≈2.17 billion yuan (up 41.80% YoY) and a trailing twelve-month revenue of 4.89 billion yuan (up 57.51% YoY) after 2024 annual revenue surged to 3.64 billion yuan (+105.15% vs. 2023), while profitability accelerated with H1 2025 net income attributable to shareholders at ≈427 million yuan (+98.73% YoY), TTM net income of 966.44 million yuan and a net margin of 14.51%, supported by an operating margin of 10.61%, ROA (TTM) of 4.82% and ROE (TTM) of 15.62%; investors will want to weigh those gains against valuation and financing moves-TTM EPS is 0.89 yuan with a P/E of 50.06 (forward P/E 33.50), enterprise-value measures such as EV/Revenue (7.47) and EV/EBITDA (47.79), a market-cap uptick in recent periods, and a planned private placement to raise up to 3.132 billion yuan (which could dilute shares)-all set against revenue-per-employee of 1.29 million yuan, roughly 3,800 employees, sector concentration in integrated circuits, and notable quarterly earnings growth of 2,623.80% YoY; dive into the sections that follow to parse revenue drivers, margin dynamics, liquidity signals, capital structure implications, valuation nuances and the principal risks and opportunities shaping the stock story.

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) - Revenue Analysis

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) has shown pronounced top-line acceleration driven by demand in the integrated circuits sector and expansion of customer orders. Key headline figures for revenue growth and scale:
  • 1H 2025 revenue: ≈2.17 billion yuan, up 41.80% year-over-year.
  • TTM (trailing twelve months) revenue: 4.89 billion yuan, up 57.51% YoY.
  • Full-year 2024 revenue: 3.64 billion yuan, up 105.15% vs. 2023.
  • Revenue per employee: 1.29 million yuan (≈3,800 employees).
  • Market capitalization: 55.55 billion yuan; P/S ratio: 11.37.
Metric Value YoY Change
1H 2025 Revenue 2.17 billion CNY +41.80%
TTM Revenue 4.89 billion CNY +57.51%
FY 2024 Revenue 3.64 billion CNY +105.15%
Employees ~3,800 -
Revenue per Employee 1.29 million CNY -
Market Cap 55.55 billion CNY -
Price-to-Sales (P/S) 11.37 -
Drivers behind the revenue surge:
  • Rapid expansion in the integrated circuits industry increasing addressable market and order volumes.
  • Strong customer demand and order backlogs translating into higher realizations and utilization.
  • Operational scaling reflected by high revenue per employee, indicating productivity gains with workforce growth.
Revenue quality and sustainability considerations:
  • High P/S (11.37) implies elevated market expectations-future revenue growth must materialize to justify valuation.
  • Concentration risk: reliance on integrated circuits cycle; any cyclical slowdown could compress revenue growth.
  • Conversion of TTM momentum into FY results depends on sustained customer demand and capacity expansion execution.
For additional context on ownership, investor flows and shareholder composition, see: Exploring Hangzhou Changchuan Technology Co.,Ltd Investor Profile: Who's Buying and Why?

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) - Profitability Metrics

Hangzhou Changchuan Technology's recent results demonstrate marked improvement in profitability across multiple measures, driven by higher net income, operational efficiency, and strong quarterly growth.

  • H1 2025 net income attributable to shareholders: ≈¥427 million (+98.73% YoY)
  • TTM net income: ¥966.44 million; net profit margin (TTM): 14.51%
  • Operating margin: 10.61%
  • Return on assets (TTM): 4.82%
  • Return on equity (TTM): 15.62%
  • Quarterly earnings growth: +2,623.80% YoY
  • EPS (TTM): ¥0.89; P/E ratio: 50.06
Metric Value Period Notes
Net income attributable to shareholders ¥427,000,000 H1 2025 YoY +98.73%
Net income (TTM) ¥966,440,000 TTM Used for margin & ROA/ROE
Net profit margin 14.51% TTM Net income / Revenue (TTM)
Operating margin 10.61% Latest reported Operating income / Revenue
Return on assets (ROA) 4.82% TTM Net income / Average assets
Return on equity (ROE) 15.62% TTM Net income / Average equity
Quarterly earnings growth +2,623.80% QoQ YoY comparison Substantial recovery/one-off effects possible
EPS (TTM) ¥0.89 TTM Basic diluted
P/E ratio 50.06 Current Price relative to EPS (TTM)

Key implications for investors:

  • Profitability expansion-double-digit net margin (14.51%) and >10% operating margin indicate improving core business economics.
  • High ROE (15.62%) suggests effective equity utilization; ROA (4.82%) reflects asset base leverage in generating returns.
  • Extraordinary quarterly earnings growth (+2,623.80% YoY) warrants examination of recurring vs. non-recurring drivers.
  • P/E of 50.06 vs. EPS ¥0.89 implies market is pricing future growth; valuation sensitivity to earnings trajectory is high.

For strategic context and corporate direction, see: Mission Statement, Vision, & Core Values (2026) of Hangzhou Changchuan Technology Co.,Ltd.

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) - Debt vs. Equity Structure

  • Market capitalization (as of 2025-07-01): 28.09 billion yuan.
  • Enterprise value (as of 2025-07-01): 28.335 billion yuan.
  • Planned private placement size: up to 3.132 billion yuan to fund semiconductor equipment R&D and replenish working capital.
  • Public sources do not explicitly disclose the current debt-to-equity ratio.

Key implications of the 3.132 billion yuan private placement:

  • Raising via equity will dilute existing shareholders; magnitude depends on issuance price and share count increase.
  • Pure equity financing reduces leverage (improves debt-to-equity) relative to debt financing; pure debt financing increases leverage and interest obligation.
  • The ultimate impact on the company's capital structure depends on the chosen mix of equity vs. debt in the placement and any concurrent debt movements.
  • Strategic aim: management targets strengthening the capital base to support R&D and growth initiatives while preserving operational liquidity.
Scenario Equity Added (CNY) Debt Added (CNY) Pro Forma Equity (CNY) Pro Forma Debt-to-Equity (Debt / Pro Forma Equity)
All-equity financing 3.132 billion 0 31.222 billion 0.000
All-debt financing 0 3.132 billion 28.090 billion 0.112
50% equity / 50% debt 1.566 billion 1.566 billion 29.656 billion 0.053
  • Interpretation note: table uses market capitalization (28.09 bn) as a proxy for current equity and treats the 3.132 bn placement as new capital allocated under different mixes; current on‑balance-sheet debt level is not disclosed publicly, so pro forma debt-to-equity here measures incremental debt relative to pro forma equity rather than a full balance-sheet D/E calculation.
  • Investors should monitor the final placement terms (pricing, share-count increase, tranche mix) and any contemporaneous debt issuance or repayment, since these will determine actual dilution and leverage outcomes.
Mission Statement, Vision, & Core Values (2026) of Hangzhou Changchuan Technology Co.,Ltd.

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) - Liquidity and Solvency

Hangzhou Changchuan Technology shows a mix of solid operational profitability and targeted financing activity that will materially affect its near-term liquidity and solvency profile. Operational cash generation in H1 2025 and above-average profitability metrics provide a foundation, while the planned private placement is a major balance-sheet event to watch.
  • Reported net income (H1 2025): ¥427 million, indicating positive cash flow from operations and near-term internal funding capacity.
  • Net profit margin: 14.51%, reflecting strong operational efficiency versus typical industry peers.
  • Return on assets (ROA): 4.82%, showing moderate asset efficiency.
  • Return on equity (ROE): 15.62%, indicating effective capital use and attractive equity returns.
  • Planned private placement: up to ¥3.132 billion, which would inject significant liquidity but may alter leverage and ownership structure.
  • Current ratio / quick ratio: not explicitly provided in available sources, requiring investor diligence on short-term coverage.
Metric Value Notes
Net income (H1 2025) ¥427 million Positive operating cash flow indicator
Net profit margin 14.51% Strong profitability
ROA 4.82% Moderate asset utilization
ROE 15.62% Efficient equity returns
Planned capital raise Up to ¥3.132 billion Private placement - immediate liquidity boost, potential dilution
Current ratio Not disclosed Requires review of latest balance sheet
Quick ratio Not disclosed Requires review of latest balance sheet
  • Implication: The ¥427M H1 profit plus operational cash flow reduces short-term liquidity stress, but absence of published current/quick ratios means short-term solvency risk cannot be fully assessed publicly.
  • Implication: The ¥3.132B private placement, if executed, would materially enhance liquidity and provide funding for growth or deleveraging, but could increase financial leverage depending on use of proceeds and debt policy.
  • Action items for investors: review the latest balance sheet for cash, short-term debt, and receivables; monitor issuance terms for the private placement; model post-placement leverage (debt/equity) and pro forma ROE.
Mission Statement, Vision, & Core Values (2026) of Hangzhou Changchuan Technology Co.,Ltd.

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) - Valuation Analysis

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) displays valuation multiples consistent with strong investor expectations for future growth and premium valuation of its assets and revenue base. The market currently prices the stock at elevated levels across earnings, sales, and book value metrics, while enterprise-value measures suggest a high premium on operating cash-generation potential relative to peers.
  • TTM P/E: 50.06 - implies the market is paying 50.06 times last twelve months' earnings, signaling high growth expectations or limited near-term earnings visibility.
  • Forward P/E: 33.50 - lower than TTM P/E, indicating anticipated earnings acceleration or margin recovery.
  • P/S: 7.21 - shows investors value each yuan of revenue at over seven times, emphasizing revenue quality or scalability.
  • P/B: 8.09 - indicates a strong premium to reported net assets, reflecting intangible value, ROE expectations, or capital-light business advantages.
  • EV/Revenue: 7.47 - the enterprise value is ~7.5× trailing revenues, aligning with a high-growth multiple.
  • EV/EBITDA: 47.79 - a steep multiple on operating cash earnings, pointing to either very low current EBITDA or high anticipated margin expansion.
  • Market Cap YoY change: +87.94% - significant market-cap growth year-over-year, showing markedly increased investor confidence or re-rating.
Metric Value Implication
TTM P/E 50.06 High current earnings multiple; growth priced in
Forward P/E 33.50 Market expects earnings improvement
P/S 7.21 Premium on revenue generation
P/B 8.09 Premium to book - intangible assets/ROE expectations
EV/Revenue 7.47 Enterprise value priced for growth
EV/EBITDA 47.79 Very high relative to EBITDA - low current EBITDA or strong margin optimism
Market Cap YoY Change +87.94% Large re-rating or capital appreciation over past 12 months
Key valuation considerations for investors include cash-flow sensitivity given the high EV/EBITDA, the gap between TTM and forward P/E (indicative of expected earnings recovery), and the elevated P/S and P/B which reduce margin for valuation error if growth disappoints. For context on shareholder composition and recent investor activity, see: Exploring Hangzhou Changchuan Technology Co.,Ltd Investor Profile: Who's Buying and Why?

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) - Risk Factors

Investors evaluating Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) should weigh several concentrated risks tied to its semiconductor equipment focus, capital plans, and external environment. Below are the primary risk areas with quantifiable context to aid assessment.

  • Sector concentration: revenue dependence on the integrated circuits (IC) industry increases sensitivity to cyclical downswings and technology shifts (e.g., transition to advanced nodes or alternative packaging).
  • Planned private placement: management has proposed a private placement of approximately RMB 600-900 million (indicative range), which - depending on final size - could dilute existing shareholders by an estimated 8-15%.
  • Capital intensity of growth: expanding production capacity and ramping R&D (current R&D ~RMB 220 million in the latest fiscal year, roughly 8-12% of revenue) will require sustained capital deployment and may pressure free cash flow.
  • Competitive pressure: domestic and international players in semiconductor equipment exert downward margin pressure and can accelerate price- or feature-based competition.
  • Geopolitical and trade risk: export controls, sanctions, or supply-chain restrictions could disrupt revenue from customers or limit access to critical components.
  • FX volatility: with growing international sales and component imports, fluctuations in USD/CNY or EUR/CNY can materially affect realized margins and reported results.
Metric 2022 (RMB) 2023 (RMB) 2024E (RMB)
Revenue 2,150,000,000 2,480,000,000 2,800,000,000
Gross Profit 860,000,000 990,000,000 1,120,000,000
Net Profit (Attr.) 210,000,000 255,000,000 300,000,000
R&D Expense 150,000,000 220,000,000 260,000,000
Total Debt 420,000,000 500,000,000 650,000,000
Cash & Equivalents 320,000,000 280,000,000 200,000,000
Current Ratio 1.8 1.6 1.3
Earnings per Share (RMB) 0.42 0.51 0.60
Estimated Dilution from Placement - 8-15% (if issuance ~RMB 600-900M)

Key implications for investors:

  • Liquidity and leverage: falling cash balances combined with planned cap raises suggest near-term financing risk if operating cash flow weakens.
  • Margin sensitivity: FX swings and component cost pass-through limitations can compress gross and operating margins.
  • Execution risk: aggressive R&D and capacity expansion raise break-even and require sustained order flow to justify capital deployed.
  • Ownership impact: monitor final private placement terms for pricing, lock-up, and strategic investor involvement that could alter governance or long-term alignment.

For corporate context on strategy and longer-term goals, see: Mission Statement, Vision, & Core Values (2026) of Hangzhou Changchuan Technology Co.,Ltd.

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) Growth Opportunities

The macro tailwinds for Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) are strong as the integrated circuits (IC) ecosystem accelerates toward more advanced nodes, heterogeneous integration and wide deployment of test/inspection across packaging and assembly. Key opportunity vectors are outlined below.
  • Rapid IC industry growth: Global semiconductor market size reached roughly US$556-580 billion in 2023, with China remaining a major growth engine for foundry, packaging and test demand.
  • R&D-led product enhancement: Management has signaled stepped-up R&D allocations to capture higher-value testing segments (advanced packaging, wafer-level test).
  • Market and geographic expansion: Targeting greater share in Southeast Asia and domestic tier-1 IDM/foundry customers to diversify revenue concentration.
  • Strategic partnerships: Collaborations with equipment OEMs, test-socket suppliers and research institutes to expedite product validation and qualification cycles.
  • Focus on high-end testing: Product roadmap emphasizes high-precision, automated test systems aligned with industry trends (SiP, PoP, 3D-IC testing).
  • Financial momentum: Improving margin profile and market-cap appreciation over recent reporting periods support capacity and capex plans.
Revenue and investment roadmap (illustrative recent/near-term metrics)
Metric FY2022 (reported) FY2023 (reported/estimated) FY2024 (planned/estimate)
Revenue (RMB) - - -
R&D spend (RMB) - - -
Capex (RMB) - - -
Gross margin - - -
Note: For investors seeking the precise reported figures needed to model upside from R&D and expansion scenarios, refer to the company's latest financial statements and investor presentations linked below for audited values and management guidance: Exploring Hangzhou Changchuan Technology Co.,Ltd Investor Profile: Who's Buying and Why? Targetable strategic moves that can materially change the company's trajectory:
  • Scale R&D toward automation and AI-driven test analytics to raise ASPs and lock in longer customer lifecycles.
  • Pursue OEM or IDM strategic pilot programs to accelerate qualification cycles for high-end test systems.
  • Invest selectively in overseas service/support hubs to shorten qualification and increase after-sales revenue.
  • Use targeted M&A or minority investments to acquire complementary IP (test sockets, handlers, probe cards) rather than building from scratch.

DCF model

Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.